Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 610-618

  Boote, D J ^a   Dennis, I F ^a   Twentyman, P R ^a   Osborne, R J ^a   Laburte, C ^a   Hensel, S ^a   Smyth, J F ^a   Brampton, M H ^a   Bleehen, N M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; VALSPODAR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030069632     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.610     Document Type: Article

References (23)

1. Pastan I, Gottesman M: Multidrug resistance in human cancer. N Engl J Med 316:1388-1393, 1987
2. Riordan JR, Ling V: Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28:51-75, 1985
3. Fojo AT, Ueda K, Salmon DJ, et al: Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269, 1987
4. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989
5. Chan HSL, Thorner PS, Haddad G, et al: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990
6. Chan HSL, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614, 1991
7. Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424, 1989
8. Twentyman PR, Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 27:1639-1642, 1991
9. Boesch D, Gaveriaux, Jachez B, et al: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Res 51:4226-4233, 1991
10. Gaveriaux C, Boesch D, Jachez B, et al: PSC-833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 2:225-234, 1991
11. Drach D, Zhao S, Drach J, et al: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance gene. Blood 80:2729-2734, 1992
12. Chaudhary P, Roninson I: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 56:85-94, 1991
13. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738, 1987
14. Yahanda AM, Adler KM, Fisher GA, et al: Phase I trial of etoposide with cyclosporine as a modulator of drug resistance. J Clin Oncol 10:1624-1634, 1992
15. Lehnert M, Kunke, K, Dalton, WS, et al: In vivo concentration of serum proteins significantly inhibits reversal of P-glycoprotein - mediated drug resistance by some chemosensitizers. Proc Am Assoc Cancer Res 31:2250, 1990 (abstr)
16. Twentyman PR, Wright KA, Boote DJ, et al: Development of a resistance modifier bioassay for use in a clinical trial of SDZ PSC 833. Proceedings of the General Motors Cancer Research Foundation International Symposium on Resistance against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities. Toronto Canada, May 1993 (abstr A27)
17. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642, 1992
18. Hande KR, Wedlund PJ, Noone RN, et al: Pharmacokinetics of high dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379-382, 1984
19. D'Incalci M, Rossi C, Zucchetti M, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566-2571, 1986
20. Arbuck S, Douglas H, Crow W, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690-1695, 1986
21. Hande KR, Anthony L, Hamilton R, et al: Identification of etoposide glucuronide as a major metabolite in the rat and rabbit. Cancer Res 48:1829-1934, 1988
22. McLeod HL. Clinical reversal of the multidrug resistance phenotype: True tumour modulation or pharmacokinetic interaction? Eur J Cancer 14:2039-2041, 1994
23. Ross DD, Wooten PJ, Tong Y, et al: Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. Blood 83:1337-1347, 1994